Upon disease progression, she was enrolled on a clinical study with the multi-kinase inhibitor pazopanib that is FDA-approved for the treatment of advanced renal cancer or sarcoma – and fortuitously has nanomolar activity against FGFR2 (in vitro IC50 to FGFR2≈350 nM) [69]. This evidence concerns the gene FGFR2 and sarcoma.